Dimerix (ASX:DXB) completed the second part of recruitment for its phase 3 kidney disease trial investigating the use of the DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Tuesday filing with the Australian bourse.
The study, named DMX-200 Action3, recruited its 144th patient, effectively completing 50% of the total recruitment for the trial, the filing said. Patients were randomized and dosed with either the medication or placebo over 35 weeks.
The company expects to complete the recruitment of all 286 adult patients in the third quarter of 2025, the filing said.
The company's shares slipped almost 1% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。